codon code aligner v. 3.7.1.1 Search Results


aligner v 3.7.1.1  (CodonCode corporation)
90
CodonCode corporation aligner v 3.7.1.1
Aligner V 3.7.1.1, supplied by CodonCode corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+code+aligner+v%2E+3%2E7%2E1%2E1/aligner+version+3+7+1/10__1007_slash_s10201___021___00670___2-45-9-8
Average 90 stars, based on 1 article reviews
aligner v 3.7.1.1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
codoncode aligner 3.7.1.1  (CodonCode corporation)
90
CodonCode corporation codoncode aligner 3.7.1.1
Codoncode Aligner 3.7.1.1, supplied by CodonCode corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+code+aligner+v%2E+3%2E7%2E1%2E1/codoncode+aligner/pmc05004594-129-20-19
Average 90 stars, based on 1 article reviews
codoncode aligner 3.7.1.1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
3711 motor vehicles & car bodies  (PACCAR Inc)
90
PACCAR Inc 3711 motor vehicles & car bodies
3711 Motor Vehicles & Car Bodies, supplied by PACCAR Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+code+aligner+v%2E+3%2E7%2E1%2E1/3711+motor+vehicles+++car+bodies/10__5296_slash_ijafr__v9i1__14053-228-130-128
Average 90 stars, based on 1 article reviews
3711 motor vehicles & car bodies - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
codoncodes 3.7.1.1  (CodonCode corporation)
90
CodonCode corporation codoncodes 3.7.1.1
Codoncodes 3.7.1.1, supplied by CodonCode corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+code+aligner+v%2E+3%2E7%2E1%2E1/codoncodes+3+7+1+1/pmc04919910-118-8-10
Average 90 stars, based on 1 article reviews
codoncodes 3.7.1.1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
raw sequences processed using codoncode aligner 3.7.1.1  (CodonCode corporation)
90
CodonCode corporation raw sequences processed using codoncode aligner 3.7.1.1
Raw Sequences Processed Using Codoncode Aligner 3.7.1.1, supplied by CodonCode corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+code+aligner+v%2E+3%2E7%2E1%2E1/raw+sequences+processed+using+codoncode+aligner+3+7+1+1/10__3852_slash_14___225r1-129-6-8
Average 90 stars, based on 1 article reviews
raw sequences processed using codoncode aligner 3.7.1.1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
assembler v. 3.7.1.1  (CodonCode corporation)
90
CodonCode corporation assembler v. 3.7.1.1
Assembler V. 3.7.1.1, supplied by CodonCode corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+code+aligner+v%2E+3%2E7%2E1%2E1/assembler+v++3+7+1+1/pmc04345460-115-17-20
Average 90 stars, based on 1 article reviews
assembler v. 3.7.1.1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
cav vaccine strain 3711  (Intervet International GmbH)
90
Intervet International GmbH cav vaccine strain 3711
Cav Vaccine Strain 3711, supplied by Intervet International GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+code+aligner+v%2E+3%2E7%2E1%2E1/cav+vaccine+strain+3711/pm15831943-23-0-10
Average 90 stars, based on 1 article reviews
cav vaccine strain 3711 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tgfβ  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc tgfβ
Ortho-PDX generation is associated with TGF-β pathway activation and increased expression of stemness-associated factors in the parental tumor. (A) Left: immunoblot analysis of TGF-β, LTBP-1 (Latent-transforming growth factor beta-binding protein 1), Latent TGF-β, active TGF-β and phosphorylated SMAD <t>2/3</t> <t>(pSMAD</t> 2/3) on whole lysates of normal mucosae (N) and patient tumors (T). Tubulin and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as loading controls. Right: quantification of the immunoblot experiment shown on the left. (B) ELISA assay performed on lysates of normal mucosae (N) and patient tumors (T) showing active TGF-β concentration. ***P < 0.001 from two-tailed t test. (C) pSMAD 2/3 staining of L5, L6 and L7 tumor sections and quantification of 5 fields/section. Magnification 20x. Bar 50 μm. (D) qRT-PCR analysis of Bmi-1, Nanog and LGR5 expression in normal mucosae and tumor tissues of CRC patients. Mean ± SD of 3 experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 from two-tailed t test.
Tgfβ, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+code+aligner+v%2E+3%2E7%2E1%2E1/TGF-beta+Antibody/pmc09275818-63-11-15
Average 96 stars, based on 1 article reviews
tgfβ - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
zo-fast 2013  (NSABP Foundation)
90
NSABP Foundation zo-fast 2013
Ortho-PDX generation is associated with TGF-β pathway activation and increased expression of stemness-associated factors in the parental tumor. (A) Left: immunoblot analysis of TGF-β, LTBP-1 (Latent-transforming growth factor beta-binding protein 1), Latent TGF-β, active TGF-β and phosphorylated SMAD <t>2/3</t> <t>(pSMAD</t> 2/3) on whole lysates of normal mucosae (N) and patient tumors (T). Tubulin and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as loading controls. Right: quantification of the immunoblot experiment shown on the left. (B) ELISA assay performed on lysates of normal mucosae (N) and patient tumors (T) showing active TGF-β concentration. ***P < 0.001 from two-tailed t test. (C) pSMAD 2/3 staining of L5, L6 and L7 tumor sections and quantification of 5 fields/section. Magnification 20x. Bar 50 μm. (D) qRT-PCR analysis of Bmi-1, Nanog and LGR5 expression in normal mucosae and tumor tissues of CRC patients. Mean ± SD of 3 experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 from two-tailed t test.
Zo Fast 2013, supplied by NSABP Foundation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+code+aligner+v%2E+3%2E7%2E1%2E1/zo+fast+2013/10__1002_slash_14651858__cd003474__pub4-2112-125-138
Average 90 stars, based on 1 article reviews
zo-fast 2013 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
square well corning 3711 microtiter plates  (Corning Life Sciences)
90
Corning Life Sciences square well corning 3711 microtiter plates
Ortho-PDX generation is associated with TGF-β pathway activation and increased expression of stemness-associated factors in the parental tumor. (A) Left: immunoblot analysis of TGF-β, LTBP-1 (Latent-transforming growth factor beta-binding protein 1), Latent TGF-β, active TGF-β and phosphorylated SMAD <t>2/3</t> <t>(pSMAD</t> 2/3) on whole lysates of normal mucosae (N) and patient tumors (T). Tubulin and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as loading controls. Right: quantification of the immunoblot experiment shown on the left. (B) ELISA assay performed on lysates of normal mucosae (N) and patient tumors (T) showing active TGF-β concentration. ***P < 0.001 from two-tailed t test. (C) pSMAD 2/3 staining of L5, L6 and L7 tumor sections and quantification of 5 fields/section. Magnification 20x. Bar 50 μm. (D) qRT-PCR analysis of Bmi-1, Nanog and LGR5 expression in normal mucosae and tumor tissues of CRC patients. Mean ± SD of 3 experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 from two-tailed t test.
Square Well Corning 3711 Microtiter Plates, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+code+aligner+v%2E+3%2E7%2E1%2E1/square+well+corning+3711+microtiter+plates/10__1016_slash_j__jala__2006__06__009-20-5-5
Average 90 stars, based on 1 article reviews
square well corning 3711 microtiter plates - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
aligner 3.7.1.1 sequencing analysis software  (CodonCode corporation)
90
CodonCode corporation aligner 3.7.1.1 sequencing analysis software
Ortho-PDX generation is associated with TGF-β pathway activation and increased expression of stemness-associated factors in the parental tumor. (A) Left: immunoblot analysis of TGF-β, LTBP-1 (Latent-transforming growth factor beta-binding protein 1), Latent TGF-β, active TGF-β and phosphorylated SMAD <t>2/3</t> <t>(pSMAD</t> 2/3) on whole lysates of normal mucosae (N) and patient tumors (T). Tubulin and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as loading controls. Right: quantification of the immunoblot experiment shown on the left. (B) ELISA assay performed on lysates of normal mucosae (N) and patient tumors (T) showing active TGF-β concentration. ***P < 0.001 from two-tailed t test. (C) pSMAD 2/3 staining of L5, L6 and L7 tumor sections and quantification of 5 fields/section. Magnification 20x. Bar 50 μm. (D) qRT-PCR analysis of Bmi-1, Nanog and LGR5 expression in normal mucosae and tumor tissues of CRC patients. Mean ± SD of 3 experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 from two-tailed t test.
Aligner 3.7.1.1 Sequencing Analysis Software, supplied by CodonCode corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+code+aligner+v%2E+3%2E7%2E1%2E1/aligner+sequence+analysis+software/pm23602355-48-8-7
Average 90 stars, based on 1 article reviews
aligner 3.7.1.1 sequencing analysis software - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
eta antagonist tbc 3711  (Encysive Pharmaceuticals)
90
Encysive Pharmaceuticals eta antagonist tbc 3711
Ortho-PDX generation is associated with TGF-β pathway activation and increased expression of stemness-associated factors in the parental tumor. (A) Left: immunoblot analysis of TGF-β, LTBP-1 (Latent-transforming growth factor beta-binding protein 1), Latent TGF-β, active TGF-β and phosphorylated SMAD <t>2/3</t> <t>(pSMAD</t> 2/3) on whole lysates of normal mucosae (N) and patient tumors (T). Tubulin and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as loading controls. Right: quantification of the immunoblot experiment shown on the left. (B) ELISA assay performed on lysates of normal mucosae (N) and patient tumors (T) showing active TGF-β concentration. ***P < 0.001 from two-tailed t test. (C) pSMAD 2/3 staining of L5, L6 and L7 tumor sections and quantification of 5 fields/section. Magnification 20x. Bar 50 μm. (D) qRT-PCR analysis of Bmi-1, Nanog and LGR5 expression in normal mucosae and tumor tissues of CRC patients. Mean ± SD of 3 experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 from two-tailed t test.
Eta Antagonist Tbc 3711, supplied by Encysive Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+code+aligner+v%2E+3%2E7%2E1%2E1/tbc3711/pmc03132177-111-13-21
Average 90 stars, based on 1 article reviews
eta antagonist tbc 3711 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Ortho-PDX generation is associated with TGF-β pathway activation and increased expression of stemness-associated factors in the parental tumor. (A) Left: immunoblot analysis of TGF-β, LTBP-1 (Latent-transforming growth factor beta-binding protein 1), Latent TGF-β, active TGF-β and phosphorylated SMAD 2/3 (pSMAD 2/3) on whole lysates of normal mucosae (N) and patient tumors (T). Tubulin and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as loading controls. Right: quantification of the immunoblot experiment shown on the left. (B) ELISA assay performed on lysates of normal mucosae (N) and patient tumors (T) showing active TGF-β concentration. ***P < 0.001 from two-tailed t test. (C) pSMAD 2/3 staining of L5, L6 and L7 tumor sections and quantification of 5 fields/section. Magnification 20x. Bar 50 μm. (D) qRT-PCR analysis of Bmi-1, Nanog and LGR5 expression in normal mucosae and tumor tissues of CRC patients. Mean ± SD of 3 experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 from two-tailed t test.

Journal: Frontiers in Oncology

Article Title: An Orthotopic Patient-Derived Xenograft (PDX) Model Allows the Analysis of Metastasis-Associated Features in Colorectal Cancer

doi: 10.3389/fonc.2022.869485

Figure Lengend Snippet: Ortho-PDX generation is associated with TGF-β pathway activation and increased expression of stemness-associated factors in the parental tumor. (A) Left: immunoblot analysis of TGF-β, LTBP-1 (Latent-transforming growth factor beta-binding protein 1), Latent TGF-β, active TGF-β and phosphorylated SMAD 2/3 (pSMAD 2/3) on whole lysates of normal mucosae (N) and patient tumors (T). Tubulin and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as loading controls. Right: quantification of the immunoblot experiment shown on the left. (B) ELISA assay performed on lysates of normal mucosae (N) and patient tumors (T) showing active TGF-β concentration. ***P < 0.001 from two-tailed t test. (C) pSMAD 2/3 staining of L5, L6 and L7 tumor sections and quantification of 5 fields/section. Magnification 20x. Bar 50 μm. (D) qRT-PCR analysis of Bmi-1, Nanog and LGR5 expression in normal mucosae and tumor tissues of CRC patients. Mean ± SD of 3 experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 from two-tailed t test.

Article Snippet: Vimentin (#5741), N-Cadherin (#13116), SLUG (#9585), ZEB1 (#3396), pSMAD 2/3 (#8828), TGFβ (#3711) were from Cell Signaling Technology, E-Cadherin (#610181) from Becton Dickinson, LTBP1 from Santa Cruz (#sc-271140).

Techniques: Activation Assay, Expressing, Western Blot, Binding Assay, Enzyme-linked Immunosorbent Assay, Concentration Assay, Two Tailed Test, Staining, Quantitative RT-PCR

Metastatic tissues lose mesenchymal traits and acquire increased chemoresistance. (A) Left: comparative immunoblot analysis of E-Cadherin (E-CAD) and Vimentin (VIM) on whole lysates of normal/peritumoral mucosa (N) and tumor tissue (T) of patient L6, orthotopic xenograft (Orthotopic), liver and lung xenograft metastases (Liver Met and Lung Met). GAPDH was used as a loading control. Right: quantification of the immunoblot experiment shown on the left. (B) Left: comparative immunoblot analysis of phosphorylated SMAD 2/3 (pSMAD 2/3) and TGF-β on whole lysates as described above. Right: quantification of the immunoblot experiment shown on the left. (C) qRT-PCR analysis of E-Cadherin (E-CAD), Vimentin (VIM), Twist, ZEB1, SNAIL, SLUG, and ZEB2 in normal/peritumoral mucosa (N) and tumor tissue (T) of patient L6, orthotopic xenograft (Orthotopic), liver and lung xenograft metastases (Liver Met and Lung Met). Mean ± SD of 3 experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 from two-tailed Student’s t test. (D) Staining of alpha Smooth Muscle Actin (αSMA) on sections of L6 orthotopic PDX and hepatic metastasis (left) and quantification of 5 sections (right). Magnification 20x, ns non-significant. (E) Left: Immunoblot analysis of human Fibroblast Activation Protein (FAP) in normal (N) and tumor (T) parental tissues of L6 patient, in orthotopic PDX (Orthotopic) and metastatic PDX (Liver Met and Lung Met). Tubulin was used as loading control. Right: quantification of the immunoblot experiment shown on the left. (F) Time course of organoid generation (orthotopic xenograft-derived organoids, OXDOs and metastatic xenograft-derived organoids, MXDOs), from the first day of culture (passage 0, P0) to subsequent passages (P3, P5 and P7, respectively after 3 weeks, 5 weeks and 7 weeks of culture). Magnification 10x. Bar 100 μM. (G) qRT-PCR analysis of E-Cadherin (E-CAD), Vimentin (VIM), SNAIL and ZEB2 on OXDOs (orange bars) and MXDOs (blue bars). *P < 0.05, **P < 0.01 and ***P < 0.001 from two-tailed Student’s t test. (H) Invasion/migration assay performed with OXDOs and MXDOs. (I) Cell viability of OXDOs (orange bars) and MXDOs (blue bars) treated with 5 μM 5-Fluorouracil (5-FU) for 6 days. Values represent mean ± SD of three independent experiments. *P < 0.05 by unpaired Student’s t test.

Journal: Frontiers in Oncology

Article Title: An Orthotopic Patient-Derived Xenograft (PDX) Model Allows the Analysis of Metastasis-Associated Features in Colorectal Cancer

doi: 10.3389/fonc.2022.869485

Figure Lengend Snippet: Metastatic tissues lose mesenchymal traits and acquire increased chemoresistance. (A) Left: comparative immunoblot analysis of E-Cadherin (E-CAD) and Vimentin (VIM) on whole lysates of normal/peritumoral mucosa (N) and tumor tissue (T) of patient L6, orthotopic xenograft (Orthotopic), liver and lung xenograft metastases (Liver Met and Lung Met). GAPDH was used as a loading control. Right: quantification of the immunoblot experiment shown on the left. (B) Left: comparative immunoblot analysis of phosphorylated SMAD 2/3 (pSMAD 2/3) and TGF-β on whole lysates as described above. Right: quantification of the immunoblot experiment shown on the left. (C) qRT-PCR analysis of E-Cadherin (E-CAD), Vimentin (VIM), Twist, ZEB1, SNAIL, SLUG, and ZEB2 in normal/peritumoral mucosa (N) and tumor tissue (T) of patient L6, orthotopic xenograft (Orthotopic), liver and lung xenograft metastases (Liver Met and Lung Met). Mean ± SD of 3 experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 from two-tailed Student’s t test. (D) Staining of alpha Smooth Muscle Actin (αSMA) on sections of L6 orthotopic PDX and hepatic metastasis (left) and quantification of 5 sections (right). Magnification 20x, ns non-significant. (E) Left: Immunoblot analysis of human Fibroblast Activation Protein (FAP) in normal (N) and tumor (T) parental tissues of L6 patient, in orthotopic PDX (Orthotopic) and metastatic PDX (Liver Met and Lung Met). Tubulin was used as loading control. Right: quantification of the immunoblot experiment shown on the left. (F) Time course of organoid generation (orthotopic xenograft-derived organoids, OXDOs and metastatic xenograft-derived organoids, MXDOs), from the first day of culture (passage 0, P0) to subsequent passages (P3, P5 and P7, respectively after 3 weeks, 5 weeks and 7 weeks of culture). Magnification 10x. Bar 100 μM. (G) qRT-PCR analysis of E-Cadherin (E-CAD), Vimentin (VIM), SNAIL and ZEB2 on OXDOs (orange bars) and MXDOs (blue bars). *P < 0.05, **P < 0.01 and ***P < 0.001 from two-tailed Student’s t test. (H) Invasion/migration assay performed with OXDOs and MXDOs. (I) Cell viability of OXDOs (orange bars) and MXDOs (blue bars) treated with 5 μM 5-Fluorouracil (5-FU) for 6 days. Values represent mean ± SD of three independent experiments. *P < 0.05 by unpaired Student’s t test.

Article Snippet: Vimentin (#5741), N-Cadherin (#13116), SLUG (#9585), ZEB1 (#3396), pSMAD 2/3 (#8828), TGFβ (#3711) were from Cell Signaling Technology, E-Cadherin (#610181) from Becton Dickinson, LTBP1 from Santa Cruz (#sc-271140).

Techniques: Western Blot, Control, Quantitative RT-PCR, Two Tailed Test, Staining, Activation Assay, Derivative Assay, Migration